Weight loss injection treatment: separating fact from the noise

The biggest misconception: the injection itself isn't what causes weight loss

Many people arrive at this topic having read that weight-loss injections are simply appetite suppressants, or that the needle somehow targets fat. Neither is accurate, and understanding the real mechanism changes how realistic your expectations will be.

Tirzepatide activates two gut-hormone receptors simultaneously (GIP and GLP-1) making it the only dual-agonist weight-loss medicine licensed in the UK. Semaglutide (Wegovy) activates the GLP-1 receptor alone. Both pathways do several things at once: they slow how quickly the stomach empties, increase signals of fullness, and reduce appetite at a hormonal level rather than through willpower or stimulants. The result is that most people on these medicines find they feel satisfied eating considerably less than before, not because they're fighting hunger, but because the hunger signals change.

Weight loss follows from that shift in eating behaviour, sustained over months. The NHS tirzepatide patient page describes the mechanism clearly and is worth reading before your first consultation. In the SURMOUNT-1 trial, participants taking the highest tirzepatide dose lost an average of around 20–21% of body weight over 72 weeks, a figure that reflects what's possible with consistent use and lifestyle engagement, not what happens automatically. Some people lose more, some less. A prescriber can help set a realistic expectation for your starting point.

The injection site itself is irrelevant to where fat is lost. You rotate sites (abdomen, thigh, upper arm) to avoid tissue irritation, not to target specific areas.

Who the licensed medicines are suitable for, and what the clinical assessment covers

A question our prescribers hear most weeks is whether a BMI of 28 or 29 'counts'. The short answer: it can, if a weight-related health condition is present.

Both tirzepatide and semaglutide carry UK licences for adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition, such as prediabetes, type 2 diabetes, high blood pressure, raised cholesterol, or obstructive sleep apnoea. BMI thresholds are applied 2.5 kg/m² lower for people from certain ethnic backgrounds under UK clinical guidance. You can explore how eligibility works in more detail if you want the full picture before booking.

BMI is the starting point for a clinical assessment, not the end of it. The prescriber looks at your full medical history: other medicines you take, any contraindications, and whether the treatment makes clinical sense given your circumstances. People who are pregnant, breastfeeding, or trying to conceive are not suitable candidates. The same applies to under-18s, and to anyone with a personal or close family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. These are hard exclusions, not suggestions.

If you want a rough sense of where your BMI sits, the NHS BMI calculator is a useful first check before speaking to a prescriber.

Side effects: what's common, what fades, and what needs prompt attention

Gastrointestinal side effects are the most frequently reported: nausea, loose stools, constipation, indigestion, and sometimes vomiting. They tend to be most noticeable in the first week or two after starting or after a dose increase, then settle for most people. Eating smaller portions, choosing bland foods initially, and staying well hydrated all help. The low starting dose on both medicines exists precisely to let your system adjust before the prescriber moves you higher.

Less common but important: both medicines carry a known (though infrequent) risk of acute pancreatitis. In January 2026 the MHRA issued a Drug Safety Update on this, advising patients to seek urgent medical attention for severe, persistent stomach pain that radiates to the back, especially if accompanied by vomiting. You can report any suspected side effects, or flag a suspect seller, through the MHRA Yellow Card scheme.

For women using oral contraceptives, tirzepatide specifically may reduce how well the pill is absorbed during the first four weeks of treatment and for four weeks after each dose increase. Adding a non-oral contraceptive method during those windows is advised. This interaction has not been demonstrated with semaglutide, though discussing your contraception with your prescriber before starting either medicine is sensible. You can read more about managing these practical considerations on the GLP-1 treatment guide.

How injection treatment fits into the wider UK landscape, NHS, private, and what to expect

Both medicines are available on the NHS, but access is tightly controlled and phased. Tirzepatide through the NHS currently requires a BMI of 40 or above alongside four or more specified conditions; eligibility broadens in stages through 2027. Wegovy is available via specialist weight management services under NICE guidance, typically with long waiting lists. The NHS England weight management injections page has the current detail on both pathways.

For people who don't meet current NHS criteria, or who'd rather not wait, a private regulated pharmacy is the alternative. Treatment through a licensed private pharmacy still requires a clinical assessment by a GPhC-registered prescriber, that step cannot be skipped, and any seller offering these medicines without one is operating outside UK law. If you're based locally, you can find out more about weight loss injections in St Helens and how to access treatment through our service there. If you're curious about how to access treatment legally, that page covers the practical steps in full.

Cost is a real consideration. Private weight-loss injection treatment is priced per pen per month and varies between providers and by dose. Since Eli Lilly raised Mounjaro's UK list price in September 2025, private prices for tirzepatide have ranged roughly £149–£375 per month depending on dose and provider, as widely reported. If the upfront cost is a concern, it's worth looking at payment plans for weight loss injections, which some services offer to spread the cost over time. At nume, one transparent price covers consultation, prescription, treatment and delivery, no subscription, no auto-renewal, and a prescriber reviews every repeat order. Current treatment pricing is on the treatment page.

Injection technique takes a little practice. Rotating sites, changing the needle with each injection, and storing your pen correctly all matter for both comfort and efficacy. Specific storage windows are set out in the Patient Information Leaflet that comes with your pen, the leaflet is the right reference, not general guidance online. Speak to our prescribers if anything about your technique or pen feels uncertain before you start.